Skip to main content

Advertisement

Table 4 Comparison of the age characteristics of the epilepsy cases in 1991–1992 and 2017

From: Impact of 19 years of mass drug administration with ivermectin on epilepsy burden in a hyperendemic onchocerciasis area in Cameroon

  1991–1992 2017
SCE SCE P PWE P
Age (years), median (IQR) 16 (13–21) 26 (20–34) <0.001 24 (20–32) <0.001
Age group
 < 10 years, n (%) 8 (9.5) 3 (2.7)   1 (1.2)  
 10–19 years, n (%) 49 (58.3) 23 (20.5)   18 (22.2)  
 20–29 years, n (%) 21 (25.0) 44 (39.3)   34 (42.0)  
 ≥ 30 years, n (%) 6 (7.1) 42 (37.5)   28 (34.6)  
Crude age-specific prevalencea    <0.001   <0.001
 < 10 years, (%) 2.5 0.4   0.1  
 10–19 years, (%) 22.3 4.9   3.8  
 20–29 years, (%) 16.3 11.6   9.0  
 ≥ 30 years, (%) 1.6 6.0   4.0  
Age at onset (years), median (IQR) 12 (8–15)b na   12 (10–14)c 0.294
Age group at onset
 < 10 years, n (%) 21 (25.0)    19 (24.4)  
 10–19 years, n (%) 49 (58.3)    57 (73.1)  
 20–29 years, n (%) 5 (6.0)    1 (1.3)  
 ≥ 30 years, n (%) 1 (1.2)    1 (1.3)  
Years since onset of epilepsy, median (IQR) 5 (2.0–7.5)b na   12.5 (7–21)b <0.001
  1. aEstimated number of people per age group (< 10, 10–19, 20–29 and ≥ 30 years) were obtained by applying the age structure of districts from the 1987 census
  2. b8 missing data
  3. Abbreviation: na, not available